期刊文献+

阿托伐他汀钙辅助治疗慢性充血性心力衰竭的疗效及安全性 被引量:2

Clinical Efficacy and Safety of Atorvastatin Calcium in Adjunctive Treatment of Chronic Congestive Heart Failure
下载PDF
导出
摘要 目的:探讨阿托伐他汀钙辅助治疗慢性充血性心力衰竭的疗效及安全性。方法:选取2015年9月—2016年9月南阳市中心医院收治的慢性充血性心力衰竭患者180例作为研究对象,采用计算机随机分组法分为观察组和对照组,每组90例。对照组患者给予常规治疗,观察组患者在对照组的基础上加用阿托伐他汀钙辅助治疗。观察两组患者的临床疗效、治疗前后心功能指标变化和不良反应发生情况。结果:观察组患者的总有效率为87.78%(79/90),明显高于对照组的58.89%(53/90),差异有统计学意义(P<0.05);治疗前,两组患者心功能指标的差异无统计学意义(P>0.05);治疗后,观察组患者左心室舒张末期内径明显低于对照组,左心室射血分数、每搏输出量及心排血量明显高于对照组,差异均有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为3.33%(3/90)、2.22%(2/90),差异无统计学意义(P>0.05)。结论:阿托伐他汀钙辅助治疗慢性充血性心力衰竭的疗效显著,可改善患者心功能,且安全性高。 OBJECTIVE: To probe into the efficacy and safety of atorvastatin calcium in adjunctive treatment of chronic congestive heart failure. METHODS: 180 patients with chronic congestive heart failure admitted into Central Hospital of Nanyang from Sept. 2015 to Sept. 2016 were extracted to be divided into observation group and control group via the random computer grouped,with 90 cases in each. The control group was given conventional treatment,while the observation group additionally received atorvastatin calcium based on the control group. The clinical efficacy,changes of cardiac parameters before and after treatment,and incidence of adverse drug reactions of two groups were observed. RESULTS: The total effective rate of observation group was 87. 78%( 79/90),significantly higher than that of control group [58. 89%( 53/90) ],with statistically significant difference( P〈0. 05). Before treatment,there was no statistically significant difference between two groups in cardiac parameters( P〈0. 05); after treatment,the left ventricular end diastolic dimension of observation group was significantly lower than that of control group,yet the left ventricular ejection fraction,stroke volume and blood flow per minute were significantly higher than that of control group,with statistically significant difference( P〈0. 05). The incidence of adverse drug reactions of observation group and control group were respectively 3. 33%( 3/90) and 2. 22%( 2/90),without any statistical significance( P〈0. 05). CONCLUSIONS: The efficacy of atorvastatin calcium in adjunctive treatment of chronic congestive heart failure is remarkable,which can effectively improve patients' cardiac function with higher safety.
出处 《中国医院用药评价与分析》 2018年第1期60-61,63,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 慢性充血性心力衰竭 阿托伐他汀钙 疗效 安全性 Chronic congestive heart failure Atorvastatin calcium Efficacy Safety
  • 相关文献

参考文献11

二级参考文献139

  • 1杨薪,刘映峰,王世祥,陈安,汪新良.前列地尔对慢性心衰大鼠心肌基质金属蛋白酶表达及纤维化的影响[J].中国动脉硬化杂志,2015,23(3):266-270. 被引量:13
  • 2刘丰彬,段立公.基质金属蛋白酶研究进展[J].山西体育科技,2005,25(3):1-4. 被引量:8
  • 3中华医学会.临床诊疗指南:心血管分册[M].北京:人民卫生出版社,2009:1-4.
  • 4Fu M. Inflammation in chronic heart failure: what is familiar, what is unfamiliar [ J ]. Eur J Heart Fail, 2009,11 (2) ,111.
  • 5Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology [J]. Eur J Heart Fail,2009,11 (2) :119.
  • 6Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure [ J ]. Circulation, 2000,102 ( 25 ) :3060.
  • 7Deswal A, Petersen N J, Feldman AM,et al. Cytokines and cytokine receptors in advanced heart failure:an analysis of the cytokine database from the Vesnarinone trial (VEST) [ J 1. Circulation ,2001,103 (16) :2055.
  • 8Mann DL. Targeted anticytokine therapy and the failing heart [ J ]. Am J Cardiol, 2005,95 ( 11 A ) : 9 C, discussion 38 C.
  • 9Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broadspectrum anti-inflammatory approaches [J]. Am J Cardiol,2005,95(11A) :17C ,discussion 38C.
  • 10Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts [ J ]. Curr Med Chem 2006,13 (16) :1877.

共引文献190

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部